<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616875</url>
  </required_header>
  <id_info>
    <org_study_id>ON/2011/3775</org_study_id>
    <secondary_id>2011-004090-82</secondary_id>
    <nct_id>NCT01616875</nct_id>
  </id_info>
  <brief_title>Bristol Bladder Trial</brief_title>
  <official_title>A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Bristol and Weston NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Bristol and Weston NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      26 patients with invasive primary transitional cell carcinoma of the bladder will receive 4&#xD;
      cycles of combination chemotherapy consisting of Cabazitaxel and Cisplatin both given&#xD;
      intravenously on day 1 of each 3 weekly cycle prior to radical cystectomy, to evaluate the&#xD;
      overall response rate and to determine whether this approach warrants further research of a&#xD;
      phase II/III study.Participation in 2 sub studies will also be offered to the participants.&#xD;
&#xD;
        1. Contrast Magnetic resonance imaging (MRI ) scans will be taken at baseline and after&#xD;
           cycle 1 and cycle 3.&#xD;
&#xD;
        2. A pilot sub study involving the circulating tumour cell concentration from blood samples&#xD;
           taken at baseline, prior to each cycle of chemotherapy and prior to surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall pathological response rate</measure>
    <time_frame>Histological assessment of radical cystectomy specimen expected to be 15 weeks after commencing study chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To record progression free survival</measure>
    <time_frame>Up to 5 years following radical cystectomy</time_frame>
    <description>From date of registration until the date of first documented progression or date of death from any cause whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess quality of life</measure>
    <time_frame>Up to 13 weeks from baseline</time_frame>
    <description>EQ-5D and EORTC QLQC30 and BLM30 will be assessed at baseline and following each cycle of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To record side effects and tolerability of treatment</measure>
    <time_frame>Up to 13 weeks from baseline</time_frame>
    <description>Common toxicity criteria adverse events (CTC AE ) Version 4.03 will be assessed at baseline and following each cycle of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years following radical cystectomy</time_frame>
    <description>From the date of registration to the date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Infiltrating Bladder Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel + Cisplatin chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 15mg/m2 Intravenous (IV)followed by Cisplatin 70mg/m2 IV on day 1 of each 21 day cycle for 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel + Cisplatin chemotherapy</intervention_name>
    <description>Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.</description>
    <arm_group_label>Cabazitaxel + Cisplatin chemotherapy</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Histologically confirmed primary transitional cell carcinoma (TCC) of the urinary&#xD;
             bladder&#xD;
&#xD;
          -  T2 to T4 disease, N0 M0 determined by computerised tomography (CT) imaging and biopsy&#xD;
             or transurethral resection&#xD;
&#xD;
          -  Eastern Co-operative Oncology Group (ECOG) Performance status 0 or 1&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) ≥60ml/min.&#xD;
&#xD;
          -  Written, informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  ECOG Performance Status ≥ 2&#xD;
&#xD;
          -  Lymph node involvement or metastatic disease&#xD;
&#xD;
          -  Prior surgery (except transurethral resection of bladder tumour), radiation,&#xD;
             che-motherapy, or other anti-cancer therapy within 4 weeks prior to enrolment&#xD;
&#xD;
          -  Active Grade ≥2 peripheral neuropathy&#xD;
&#xD;
          -  Active secondary cancers&#xD;
&#xD;
          -  History of severe hypersensitivity reaction (≥Grade 3) to polysorbate 80 containing&#xD;
             drugs&#xD;
&#xD;
          -  Other concurrent serious illness or medical conditions&#xD;
&#xD;
          -  Inadequate organ function as evidenced by peripheral blood counts at enrolment:&#xD;
&#xD;
          -  Electrocardiogram (ECG) evidence of uncontrolled cardiac arrhythmias, angina pectoris,&#xD;
             and/or hypertension, history of congestive heart failure, or myocardial infarction&#xD;
             within last 6 months.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Active uncontrolled gastro-oesophageal reflux disease (GORD).&#xD;
&#xD;
          -  Active infection requiring systemic antibiotic or anti-fungal medication&#xD;
&#xD;
          -  Participation in another clinical trial with any investigational drug within 30 days&#xD;
             prior to study enrolment.&#xD;
&#xD;
          -  Concurrent or planned treatment with strong inhibitors of cytochrome P450 3A4/5. A&#xD;
             1-week washout period is necessary for patients who are already on these treatments.&#xD;
&#xD;
          -  Concurrent or planned treatment with strong inducers of cytochrome P450 3A4/5. A&#xD;
             1-week washout period is necessary for patients who are already on these treatments.&#xD;
&#xD;
          -  Contraindications to cisplatin.&#xD;
&#xD;
          -  Patient with reproductive potential not implementing an accepted and effective method&#xD;
             of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit K Bahl</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Bristol and Weston NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bristol Haematology + Oncology Centre, Horfield Road</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>Transitional cell carcinoma</keyword>
  <keyword>Urothelial cancer</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Cabazitaxel</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Neo adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

